NUVALENT INC
NASDAQ: NUVL (Nuvalent, Inc.)
Kemas kini terakhir: semalam, 3:50PM80.30
-1.76 (-2.14%)
| Penutupan Terdahulu | 82.06 |
| Buka | 81.25 |
| Jumlah Dagangan | 396,998 |
| Purata Dagangan (3B) | 428,408 |
| Modal Pasaran | 5,705,524,224 |
| Harga / Buku (P/B) | 5.24 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.49 |
| Nisbah Semasa (MRQ) | 23.07 |
| Aliran Tunai Operasi (OCF TTM) | -153.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.21 M |
| Pulangan Atas Aset (ROA TTM) | -18.63% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Nuvalent, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.83% |
| % Dimiliki oleh Institusi | 108.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 30 Sep 2024 | 1,687,064 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 134.00 (BMO Capital, 66.87%) | Beli |
| Median | 125.00 (55.67%) | |
| Rendah | 100.00 (UBS, 24.53%) | Pegang |
| Purata | 119.67 (49.03%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 96.30 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 13 Nov 2024 | 134.00 (66.87%) | Beli | 90.34 |
| UBS | 24 Oct 2024 | 100.00 (24.53%) | Pegang | 93.63 |
| JP Morgan | 04 Oct 2024 | 125.00 (55.67%) | Beli | 104.93 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BALCOM ALEXANDRA | - | - | 0 | 0 |
| PELISH HENRY E. | - | - | 0 | 0 |
| PORTER JAMES RICHARD | - | 87.42 | -27,000 | -2,360,340 |
| Jumlah Keseluruhan Kuantiti Bersih | -27,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,360,340 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 87.42 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PORTER JAMES RICHARD | Pegawai | 19 Dec 2024 | Pelaksanaan pilihan | 22,000 | - | - |
| BALCOM ALEXANDRA | Pegawai | 17 Dec 2024 | Pelaksanaan pilihan | 13,700 | - | - |
| PORTER JAMES RICHARD | Pegawai | 16 Dec 2024 | Jual automatik (-) | 27,000 | 87.42 | 2,360,340 |
| PORTER JAMES RICHARD | Pegawai | 16 Dec 2024 | Pelaksanaan pilihan | 27,000 | - | - |
| PELISH HENRY E. | Pegawai | 16 Dec 2024 | Pelaksanaan pilihan | 10,414 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Dec 2024 | Pengumuman | Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 09 Dec 2024 | Pengumuman | Nuvalent Appoints Grant Bogle to Board of Directors |
| 26 Nov 2024 | Pengumuman | Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 12 Nov 2024 | Pengumuman | Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Pengumuman | From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |